Risankizumab and Tulisokibart for Ulcerative Colitis

Miguel Regueiro, MD

Professor of Medicine
Chief, Digestive Disease Institute
Cleveland Clinic, Cleveland

We rarely discuss early phase trials in The Regueiro Report because I like to highlight treatments that are close to approval and available to patients soon. However, in this report, we are highlighting a phase 2 trial that offers a promising new mechanism of action for our patients with inflammatory bowel disease.

The first study in our report is a